FLT3 and acute myeloid leukemia: FLT3 tyrosine kinase inhibitors (TKI)—such as quizartinib, gilteritinib, and crenolanib—have activity as single agents in FLT3-mutated AML and several case studies showed that at least a number of elderly FLT3-ITD AML patients were able to be successfully bridged to alloHSCT by treatment with TKI monotherapy [85,86].